Desipramine

CHEMBL72 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
266.4 g/mol
LogP
4.9
Phase
4

A tricyclic antidepressant and active metabolite of imipramine that primarily inhibits norepinephrine reuptake, used for major depression, neuropathic pain, and sometimes ADHD. It has fewer anticholinergic and sedative effects than many other tricyclic antidepressants.

Peso Molecular

266,4000 g/mol

LogP

4,90

TPSA

15,30 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Mecanismo de Ação

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNCCCN1c2ccccc2CCc2ccccc21

InChI

InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3

Molecular Formula

C18H22N2

HBD / HBA

1 / 2

Ligações Rotacionáveis

4

Átomos Pesados

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A tricyclic antidepressant and active metabolite of imipramine that primarily inhibits norepinephrine reuptake, used for major depression, neuropathic pain, and sometimes ADHD. It has fewer anticholinergic and sedative effects than many other tricyclic antidepressants.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Desipramine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL72. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2995. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.